1. Home
  2. MTDR vs COGT Comparison

MTDR vs COGT Comparison

Compare MTDR & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MTDR

Matador Resources Company

HOLD

Current Price

$60.36

Market Cap

7.3B

Sector

Energy

ML Signal

HOLD

Logo Cogent Biosciences Inc.

COGT

Cogent Biosciences Inc.

HOLD

Current Price

$32.49

Market Cap

5.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MTDR
COGT
Founded
2003
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.3B
5.9B
IPO Year
2011
2018

Fundamental Metrics

Financial Performance
Metric
MTDR
COGT
Price
$60.36
$32.49
Analyst Decision
Buy
Strong Buy
Analyst Count
15
15
Target Price
$63.07
$36.21
AVG Volume (30 Days)
1.5M
1.4M
Earning Date
05-06-2026
05-06-2026
Dividend Yield
2.38%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,696,277,000.00
$7,871,000.00
Revenue This Year
$7.15
N/A
Revenue Next Year
$7.63
$1,733.58
P/E Ratio
N/A
N/A
Revenue Growth
5.46
N/A
52 Week Low
$37.14
$4.55
52 Week High
$66.84
$43.73

Technical Indicators

Market Signals
Indicator
MTDR
COGT
Relative Strength Index (RSI) 53.75 30.56
Support Level $53.44 $14.00
Resistance Level $63.88 $37.69
Average True Range (ATR) 1.84 1.36
MACD -0.26 -0.33
Stochastic Oscillator 63.93 0.59

Price Performance

Historical Comparison
MTDR
COGT

About MTDR Matador Resources Company

Matador Resources Co is an independent energy company engaged in the exploration, development, production, and acquisition of oil and natural gas resources. The majority of the company's assets are located in the United States, with an emphasis on oil and natural gas shale and other unconventional plays. Along with maintaining a portfolio of oil and natural gas properties, Matador works to identify and develop midstream opportunities that support and enhance its exploration and development business. The Company has two reportable business segments: exploration and production and midstream. The company generates majority of its revenue from the exploration and production segment.

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Share on Social Networks: